固形腫瘍検査の世界市場レポート：動向、予測、競合分析（～2031年）

世界の固形腫瘍検査市場の将来は、病院、製薬・バイオテクノロジー企業、受託研究機関、学術研究機関の各市場における機会で有望視されています。世界の固形腫瘍検査の市場規模は、2025年～2031年のCAGRが3.5%で、2031年までに推定1兆6,992億米ドルに達すると予想されます。この市場の主な促進要因は、サプリメントやステロイドの利用の増加、喫煙や飲酒などの不健康な習慣の増加です。

• Lucintelの予測によると、用途別では、皮膚腫瘍および関連疾患の世界の発生率の増加により、メラノーマが予測期間中に最も高い成長を遂げる見込みです。
• 最終用途別では、腫瘍と慢性疾患の罹患率の上昇により、病院が最も高い成長を示すと予想されます。
• 地域別では、北米が、堅牢なヘルスケアインフラに支えられた様々な臓器特異的がん症例の増加により、予測期間中に最大の成長を遂げる見込みです。

固形腫瘍検査市場の戦略的成長機会

固形腫瘍検査分野で注目されている幾何学的な進展は、構成要素であるジオシステムの基盤領域に関連した多様な戦略的除外オプションを包含しています。特定の潜在的価値の開発は、診断プロセスや治療結果を向上させる課題に対処するのに役立ちます。

• 個別化医療の導入：個別化医療は、個々の患者に適した独自の検査を設計することを可能にしました。遺伝子を総合的に調査することで、病気の治療や患者の健康状態の改善により効果的な新しい戦略を考案することができます。
• リキッドバイオプシー市場の進展：非侵襲的検査の動向の高まりを見ると、企業はリキッドバイオプシー・システムとサービスを強化する機会を得ています。この動向は、患者を快適にさせるだけでなく、治療効果のより適切な測定を可能にします。
• 診断へのAI技術の活用：固形腫瘍検査へのAIの応用は、インテリジェントな診断ソリューションの開発に新たな道を開きます。これらは、膨大な情報を体系的にふるいにかけ、検査の精度を向上させ、ワークフローの効率を高め、診断に至るまでの時間を短縮することができます。
• 早期発見の必要性の高まり：がんとその初期症状に対する理解が深まるにつれ、より優れたスクリーニング・ツールの必要性が高まっています。したがって、より優れた早期発見検査を市場に提供するために投資する主要企業は、業界におけるこのニーズの高まりからより多くの利益を得ることができ、ひいては拡大する顧客層からより大きな市場シェアを得ることにつながります。
• 先進市場のターゲット - 海外事業の開拓：新興市場、特にアジアとアフリカの市場は、固形腫瘍検査ビジネスにとって素晴らしい道であることが証明される見込みです。これらの地域に戦略的に参入できる企業は、より良い診断方法を求める患者が増加することに気づくと思われます。

こうした将来を見据えた成長戦略は、精密医療、テクノロジー、斬新な診断ソリューションに焦点を当てることで、固形腫瘍検査市場を再定義しています。このような機会を追求するプロバイダーは、より多くの市場シェアを獲得し、患者に提供されるケアの質を向上させると思われます。

固形腫瘍検査市場の促進要因・課題

現在の市場内の固形腫瘍検査と同様に、今後の固形腫瘍検査市場も、促進要因としても抑制要因としても機能するいくつかの技術的、経済的、規制的要因に悩まされています。環境が変化し続ける中、利害関係者にとってこれらの力学を理解することは重要です。

固形腫瘍検査市場の促進要因は以下の通りです：

1. 技術の進歩：リキッドバイオプシーやゲノムプロファイリングなどの検査法における技術革新が市場を活性化しています。最も重要なことは、これらの技術革新により精度が向上し、特定の治療法がターゲットとなり、多様な治療法への患者のアクセスが改善されることです。

2. がん罹患率の増加：世界のがん罹患率の増加により、より優れた検査技術が求められています。早期診断サービスや適切な治療法を求める人が増えるにつれ、固形腫瘍検査市場は成長を続けています。

3. 個別化治療へのシフト：精密医療への関心の高まりにより、固形腫瘍検査のパラダイムシフトが起こっています。患者や医療提供者は、より効果的な標的療法で治療できる特定の変異を明らかにできる検査をますます求めるようになっています。

4. 政府の政策奨励：規制当局は、革新的な検査アイデアを推進し、新しい機器の市場導入期間を短縮しています。このような雰囲気は研究開発活動の実施を後押しし、最終的に最新かつ先進的な診断機器の供給を増加させます。

5. ヘルスケア財政の成長：固形腫瘍検査市場の成長は、公的機関および民間機関によるヘルスケアインフラとバイオテクノロジーへの投資によって促進されます。資金調達の改善により、洗練された診断アプローチの創出と利用が促進されます。

固形腫瘍検査市場の課題は以下の通りです：

1. 規制上のハードル：規制当局の承認が得られる場合もありますが、新技術の承認を得るのは一筋縄ではいきません。革新的な企業は最先端のソリューションの上市に問題を抱え、競合に悪影響を及ぼします。

2. 市場の細分化：二次性悪性腫瘍の検査市場は統合性が低く、多くの利害関係者が異なるサービスを提供しています。この断片化は、医療従事者や患者の混乱を招き、その結果、検査に関する選択を誤らせます。

固形腫瘍検査市場の開拓を支える要因と拡大を阻む要因のバランスは極めて明白です。患者ケアを改善し、がん診断の効果的で進歩的な開発を促進するためには、利用可能な技術開発を活用し、課題に対処することが不可欠です。

目次

第1章 エグゼクティブサマリー

第2章 世界の固形腫瘍検査市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析（2019年～2031年）

• マクロ経済動向（2019年～2024年）と予測（2025年～2031年）
• 世界の固形腫瘍検査市場の動向（2019年～2024年）と予測（2025年～2031年）
• 世界の固形腫瘍検査市場：タイプ別
  • 遺伝子検査
  • 従来型検査
• 世界の固形腫瘍検査市場：用途別
  • 前立腺
  • 胸部
  • 大腸
  • 子宮内膜
  • 肺
  • 悪性黒色腫
  • その他
• 世界の固形腫瘍検査市場：最終用途別
  • 病院
  • 製薬・バイオテクノロジー企業
  • 受託研究機関
  • 学術研究機関

第4章 市場動向と予測分析：地域別（2019年～2031年）

• 地域別の固形腫瘍検査市場
• 北米の固形腫瘍検査市場
• 欧州の固形腫瘍検査市場
• アジア太平洋の固形腫瘍検査市場
• その他地域の固形腫瘍検査市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界の固形腫瘍検査市場の成長機会：タイプ別
  • 世界の固形腫瘍検査市場の成長機会：用途別
  • 世界の固形腫瘍検査市場の成長機会：最終用途別
  • 世界の固形腫瘍検査市場の成長機会：地域別
• 世界の固形腫瘍検査市場における新たな動向
• 戦略分析
  • 新製品開発
  • 世界の固形腫瘍検査市場の生産能力拡大
  • 世界の固形腫瘍検査市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業プロファイル

• Agilent Technologies
• MYRIAD GENETICS
• Biocare Medical
• ILLUMINA
• F. Hoffmann-La Roche
• QIAGEN
• MedGenome Labs
• Thermo Fisher Scientific
• Abbott Laboratories
• QUEST DIAGNOSTICS

The future of the global solid tumor testing market looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1699.2 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are the increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.

• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
• In terms of regions, North America is expected to witness the largest growth over the forecast period due to a rise in various organ-specific cancer cases, supported by a robust healthcare infrastructure.

Gain Valuable Insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Solid Tumor Testing Market

The solid tumor testing market is being shaped by emerging trends in the field that are changing the aspects of diagnostics and treatment methods. These trends are marked by differences in technologies, changes in the healthcare system, and a shift in focus toward the patient.

• Liquid Biopsy Technology: Liquid biopsy technology includes the examination of liquid samples from patients to identify solid tumors by analyzing circulating tumor DNA (ctDNA). Monitoring tumor behavior and its changes can help improve the personalization of treatment and decrease the number of invasive procedures used.
• Genomic Profiling: Comprehensive genomic profiling is becoming an essential component of cancer management as it helps in the detection of mutations in different tumors. In this context, agents that promote the creation of drugs that target specific molecules are likely to be beneficial to patients, especially in cases of cancer types with metastatic potential.
• Integration of AI and Machine Learning: The use of AI and machine learning in performing solid tumor tests improves the accuracy and speed of diagnosis. Such technologies analyze vast amounts of data to identify potential trends and forecast the outcomes of treatments, assisting doctors in formulating appropriate treatment measures.
• Increased Focus on Early Detection: There is an increasing focus on the early detection of solid tumors, as this significantly increases the chances of successfully treating affected individuals. There is a need to develop strategies for providing regular check-ups and advanced diagnostic approaches to ensure that cancers are detected at an earlier stage when they are most treatable.
• Regulatory Attitude Towards Technology: Regulatory authorities have started to recognize and promote more innovative and novel diagnostic solutions, which accelerate the approval of new technologies and streamline the approval systems. This scenario is supportive of both the establishment and practice of research and development, which will, in turn, increase the chances of these sophisticated testing procedures becoming commonplace in routine use.

These new trends are revitalizing the solid tumor testing segment of the market by strengthening the capabilities of diagnostics, encouraging targeted approaches, and improving the healthcare provided. With the rapid rate of technological changes, it will not be surprising to find that all these trends will be integrated in further tackling the problems associated with cancer.

Recent Developments in the Solid Tumor Testing Market

The market for solid tumor testing has its share of developments that stand out with improvements in the accuracy and management of treatment. Such trends are all towards an increase in personalized medicine and a demand for advancements in treatment technology concerning cancer.

• Liquid Biopsy Advancements: Recent developments in the liquid biopsy field have allowed for the non-invasive detection of solid tumors via the analysis of ctDNA bioassays. This development significantly augments the surveillance of patients and any changes that may be made in the course of treatment, showing how the tumor is behaving as well as the effects of the treatment given.
• Genomic Profiling Approvals: The endorsement of policies for the approval of diverse molecular profiling tests by health regulators has made access to selected therapies easier. Using these tests, oncologists can isolate certain mutations that, in turn, lead to tailored surgical intervention plans that improve positive outcomes and reduce negative effects in patients.
• AI-Driven Diagnostics: The use of artificial intelligence systems in testing solid tumors is changing the way things are done in the industry. AI techniques are better equipped to evaluate multifaceted data compared to traditional approaches, thereby making diagnosis and treatment processes faster by providing more informed treatment options for patients.
• Collaborative Research Initiatives: Collaboration between universities and biotech firms has fostered the improvement of cancer diagnostic techniques. International collaboration, for example, supports technology development and improves testing strategies so that advanced technologies reach clinicians more quickly.
• Global Standardization Efforts: The global standardization movement of solid tumor biological diagnostic testing procedures is gaining the momentum it deserves. It seeks the harmonization of diagnostic testing strategies so that uniformity and reproducibility of particular tests are achieved, which will, in turn, improve the quality of care for patients worldwide.

These key advancements have benefited the solid tumor testing market through better diagnosis, extended treatment alternatives, and effective patient management. It is clear that emphasizing the challenges and possible solutions brings about more opportunities for future developments in this field.

Strategic Growth Opportunities for Solid Tumor Testing Market

The geometrical progression that attracts attention in the area of solid tumor testing encompasses diverse strategic exclusion options related to the component geosystems basis territory diversified. The development of specific potential values helps address the challenges that enhance the diagnosis processes and treatment outcomes.

• Introduction of Personalized Medicine: Personalized medicine has made it possible to design unique tests that are appropriate for an individual patient. A comprehensive investigation of genes can help devise new strategies that are more effective in treating diseases and improving the health status of patients.
• Advancing the Liquid Biopsy Market: Looking at the growing trend of non-invasive testing, companies have an opportunity to enhance their liquid biopsy systems and services. This trend helps not only to make patients comfortable but also allows better measurement of treatment response.
• Using AI Technology for Diagnostics: The application of AI in solid tumor testing creates new pathways for the development of intelligent diagnostic solutions. These can sift through a massive amount of information systematically to improve the accuracy of tests, increase workflow efficiency, and reduce the time taken to arrive at a diagnosis.
• There is a growing need for early detection: Increased understanding of cancer and its early symptoms has necessitated the need for better screening tools. Thus, companies that invest in bringing forth better early detection tests for the market can gain more from this growing need in the industry, which, in turn, leads to a larger market share from the expanding clientele.
• Developed Markets Target-Expansion of Overseas Operations: Emerging markets, especially in Asia and Africa, will prove to be great avenues for the solid tumor testing business. Companies that can strategically enter these areas will find an increasing number of patients seeking better ways to diagnose their diseases.

These forward-looking growth strategies are redefining the solid tumor testing market by focusing on precision medicine, technology, and novel diagnostic solutions. Providers who pursue these opportunities will capture more market share and enhance the quality of care provided to patients.

Solid Tumor Testing Market Driver and Challenges

Similar to solid tumor testing within the market, the upcoming solid tumor testing market also suffers from several technological, economic, and regulatory factors that act as both enablers and inhibitors. Understanding these dynamics is important for stakeholders as the environment continues to change.

The factors responsible for driving the solid tumor testing market include:

1. Technological Advancements: Technological innovations in testing methods, including liquid biopsies and genomic profiling, are fueling the market. Most importantly, these innovations increase accuracy, target specific therapies, and improve patient access to diverse treatments.

2. Increasing Cancer Incidence: The increasing global burden of cancer is demanding better testing techniques. As more people request early diagnosis services and suitable therapies, the market for solid tumor testing continues to grow.

3. Shift Towards Individualized Treatment: There is a paradigm shift in solid tumor testing driven by an increasing focus on precision medicine. More and more, patients and providers are looking for tests that can reveal particular mutations that can then be treated with more effective targeted therapies.

4. Government Policy Encouragement: Regulatory authorities are promoting innovative testing ideas and shortening the duration of introducing new devices to the market. This atmosphere favors conducting R&D activities, which ultimately results in an increased supply of modern and advanced diagnostic equipment.

5. Growth in Healthcare Financing: Growth in the solid tumor testing market is fueled by investment in healthcare infrastructure and biotechnology by public and private institutions. Improved funding facilitates the creation and use of sophisticated diagnostic approaches.

Challenges in the solid tumor testing market include:

1. Regulatory Hurdles: Although regulatory endorsement is acquired in some cases, it is not straightforward to gain approval for new technology. Innovative companies experience problems launching their cutting-edge solutions, which negatively impacts competition.

2. Market Fragmentation: The market for testing malignant secondary tumors is poorly consolidated, and many stakeholders offer different services. This fragmentation leads to confusion among medical practitioners and patients, resulting in poor choices regarding testing.

The balance of factors that support the development and barriers to the expansion of the solid tumor testing market is quite evident. It is essential to utilize available technological developments and address challenges to improve patient care and foster the effective and progressive development of cancer diagnostics.

List of Solid Tumor Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies solid tumor testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include-

• Agilent Technologies
• MYRIAD GENETICS
• Biocare Medical
• ILLUMINA
• F. Hoffmann-La Roche
• QIAGEN
• MedGenome Labs
• Thermo Fisher Scientific
• Abbott Laboratories
• QUEST DIAGNOSTICS

Solid Tumor Testing by Segment

The study includes a forecast for the global solid tumor testing market by type, application, end use, and region.

Solid Tumor Testing Market by Type [Analysis by Value from 2019 to 2031]:

• Genetic Testing
• Conventional Testing

Solid Tumor Testing Market by Application [Analysis by Value from 2019 to 2031]:

• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others

Solid Tumor Testing Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions

Solid Tumor Testing Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Solid Tumor Testing Market

The solid tumor testing market is undergoing dramatic changes in some countries primarily due to technological breakthroughs and increases in healthcare expenditure and focus on personalized medicine. This is particularly true for the United States, China, Germany, India, and Japan, each of which is progressing in specific areas to enhance diagnostic devices and therapeutic approaches.

• USA: There is rapid development of liquid biopsy technologies, which revolutionize the way cancer is diagnosed through non-invasive methods for solid tumors that do not require invasive surgery. With the increasing number of approvals for genomic profiling tests, it is possible to develop targeted therapies. Apart from this, partnerships between biotech companies and healthcare providers enhance diagnostics.
• China: Such development in China regarding the solid tumor market is observed primarily because of the influx of public funds in the field of biotechnology, including healthcare. An increase in inhibitory activity in management, including management of precision medicine programs, is witnessed with a growing volume in the utilization of complicated genomic tests. No affordable management has grown this change for focal management specifically at centers, as they reduce the rate of delay and assist in developing better management strategies.
• Germany: Germany's solid tumor testing market is supported by impressive research activity and collaboration between research institutes and businesses. The country is moving toward next-generation sequencing (NGS) technologies, which further improve diagnostic accuracy and support the implementation of specific treatments. Innovative testing approaches are also being accepted, as improvements in regulatory guidance encourage the development of new diagnostic methods.
• India: The solid tumor testing market is fueled by the growing incidence of cancer among the population in India. Low-cost genomic diagnostic tests, developed for the majority of the population by emerging companies, promote early diagnosis and treatment personalization. Improvements in cancer diagnostics are also aided by increased public awareness and government policies.
• Japan: Japan is expanding its solid tumor testing market by employing new imaging methodologies along with NGS in the field of solid tumors. The government is encouraging doctors to adopt precision medicine concepts, resulting in more mechanisms for treating cancers. Marketing drafts created in cooperation with Japanese companies and foreign companies have expanded the supply of new diagnostic methods.

Features of the Global Solid Tumor Testing Market

Market Size Estimates: Solid tumor testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Solid tumor testing market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Solid tumor testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, end use, and regions for the solid tumor testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Solid Tumor Testing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Solid Tumor Testing Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Solid Tumor Testing Market by Type
  • 3.3.1: Genetic Testing
  • 3.3.2: Conventional Testing
• 3.4: Global Solid Tumor Testing Market by Application
  • 3.4.1: Prostate
  • 3.4.2: Breast
  • 3.4.3: Colorectal
  • 3.4.4: Endometrial
  • 3.4.5: Lung
  • 3.4.6: Melanoma
  • 3.4.7: Others
• 3.5: Global Solid Tumor Testing Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Pharmaceutical & Biotechnology Companies
  • 3.5.3: Contract Research Organizations
  • 3.5.4: Academic Research Institutions

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Solid Tumor Testing Market by Region
• 4.2: North American Solid Tumor Testing Market
  • 4.2.1: North American Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.2.2: North American Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.3: European Solid Tumor Testing Market
  • 4.3.1: European Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.3.2: European Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.4: APAC Solid Tumor Testing Market
  • 4.4.1: APAC Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.4.2: APAC Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions
• 4.5: ROW Solid Tumor Testing Market
  • 4.5.1: ROW Market by Application: Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, and Others
  • 4.5.2: ROW Market by End Use: Hospitals, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic Research Institutions

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Solid Tumor Testing Market by Type
  • 6.1.2: Growth Opportunities for the Global Solid Tumor Testing Market by Application
  • 6.1.3: Growth Opportunities for the Global Solid Tumor Testing Market by End Use
  • 6.1.4: Growth Opportunities for the Global Solid Tumor Testing Market by Region
• 6.2: Emerging Trends in the Global Solid Tumor Testing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Solid Tumor Testing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Solid Tumor Testing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Agilent Technologies
• 7.2: MYRIAD GENETICS
• 7.3: Biocare Medical
• 7.4: ILLUMINA
• 7.5: F. Hoffmann-La Roche
• 7.6: QIAGEN
• 7.7: MedGenome Labs
• 7.8: Thermo Fisher Scientific
• 7.9: Abbott Laboratories
• 7.10: QUEST DIAGNOSTICS